Skip to main content
    C

    Contineum Therapeutics, Inc. Class A Common Stock (CTNM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.67
    -0.19 (-1.93%)

    Market Cap: $387.16M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Financials: Revenue, Profit and Cash Flow

    Updated Nov 3, 2026. Financial statements from company filings, amounts in US dollars.

    Contineum Therapeutics, Inc. Class A Common Stock reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$59.98M, operating cash flow was -$55.31M and free cash flow was -$55.54M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$18.70M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $68.06M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0-100.0%N/AN/AN/A
    Dec 2023$50.00MN/A100.0%32.2%45.4%
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2021 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
    Revenue$0$0$50.00M$0$0
    Cost of revenue$0$0$0$329.00KN/A
    Gross profit$0$0$50.00M-$329.00KN/A
    Research and development$51.52M$38.42M$27.60M$16.89M$22.36M
    Operating income-$68.06M-$50.89M$16.08M-$22.72M-$28.65M
    Net income-$59.98M-$42.26M$22.72M-$24.25M-$29.00M
    EBITDAN/AN/A$16.09MN/A-$28.34M
    Fiscal years ended Dec 2021 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$242.00K$0$0$0$0
    Gross profit$0$0$0-$85.00K$0$0$0$121.00K$0$0$0-$37.00K
    Operating income-$20.97M-$17.43M-$16.90M-$17.11M-$14.93M-$17.90M-$18.11M-$17.05M-$12.97M-$10.94M-$9.93M-$9.68M
    Net income-$18.70M-$15.15M-$14.46M-$15.16M-$12.79M-$16.04M-$15.99M-$14.56M-$10.27M-$9.01M-$8.42M-$7.77M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $2.34M by $73.26M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
    Total assets$276.64M$212.85M$130.39M$50.64M$70.52M
    Current assets$267.92M$206.39M$127.71M$48.39M$69.78M
    Cash and equivalents$75.60M$21.94M$15.53M$5.57M$4.63M
    Total liabilities$15.65M$14.78M$5.70M$11.37M$8.93M
    Short-term debt$2.34M$1.45M$464.00K$5.06M$1.25M
    Long-term debtN/AN/AN/AN/A$3.66M
    Shareholder equity$260.99M$198.07M-$67.94M$39.27M$61.59M
    Fiscal years ended Dec 2021 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$256.99M$250.37M$261.35M$276.64M$190.85M$182.89M$198.26M$212.85M$216.03M$221.35M$123.56M$130.39M
    Total liabilities$11.57M$10.71M$11.31M$15.65M$10.38M$11.50M$13.50M$14.78M$5.81M$3.85M$6.57M$198.32M
    Cash and equivalents$75.20M$14.71M$20.16M$75.60M$42.63M$20.78M$22.47M$21.94M$40.89M$77.23M$16.26M$15.53M
    Shareholder equity$245.42M$239.66M$250.04M$260.99M$180.47M$171.39M$184.77M$198.07M$210.23M$217.50M-$75.63M-$67.94M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
    Operating cash flow-$55.31M-$32.84M$19.35M-$20.12M-$26.27M
    Capital expenditures$231.00K$514.00K$414.00K$118.00K$168.00K
    Free cash flow-$55.54M-$33.36M$18.93M-$20.24M-$26.43M
    Share repurchases$256.00K$0$371.00KN/AN/A
    Investing cash flow-$3.71M-$69.74M-$65.57M$22.30M-$64.97M
    Financing cash flow$112.69M$109.00M$56.18M-$1.24M$79.84M
    Fiscal years ended Dec 2021 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$11.06M-$11.50M-$16.27M-$13.04M-$12.20M-$15.66M-$14.41M-$10.20M-$6.17M-$8.50M-$7.97M-$10.70M
    Capital expendituresN/A$6.00K$312.00K$42.00K$98.00K$44.00K$47.00K$166.00K$82.00K$119.00K$147.00K$309.00K
    Free cash flowN/A-$11.51M-$16.58M-$13.08M-$12.29M-$15.71M-$14.46M-$10.37M-$6.25M-$8.62M-$8.12M-$11.01M
    Last 12 quarters

    Frequently Asked Questions About CTNM

    What is Contineum Therapeutics, Inc. Class A Common Stock's annual revenue?

    Contineum Therapeutics, Inc. Class A Common Stock reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Contineum Therapeutics, Inc. Class A Common Stock profitable?

    No. Contineum Therapeutics, Inc. Class A Common Stock reported net income of -$59.98M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does CTNM generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$55.31M minus capital expenditures of $231.00K produced free cash flow of -$55.54M.

    How much debt does Contineum Therapeutics, Inc. Class A Common Stock have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $2.34M and cash and equivalents of $75.60M.